NHO Revive Expands Reach at SCRS Global Site Solutions Summit 2026
News related to:NHO Revive · 1 min read
NE, UNITED STATES, October 13, 2026 /CourierPR/ -- NHO Revive, a joint initiative between Nebraska Hematology Oncology (NHO) and Revive Research Institute, is set to make its presence felt at the SCRS Global Site Solutions Summit 2026. The event, hosted by the Society for Clinical Research Sites (SCRS), will take place from October 15 to 18 in Orlando, Florida.
NHO Revive, which is part of the Revival Site Network, aims to connect with industry professionals who share its mission of improving treatment options for patients with blood disorders and cancer. The team will be present at Booth #513, offering insights and collaborating with sponsors, contract research organizations (CROs), and other research sites.
The summit is a platform for attendees to learn from one another and discuss ways to enhance clinical trial processes. NHO Revive's participation is particularly significant as it seeks to understand the needs of potential partners before a study begins. This will enable the team to better plan for start-up, enrollment, and data quality.
The team's presence at the summit also reflects its dedication to shared standards of quality, accountability, and patient-centered care. As part of the Revival Site Network, NHO Revive works closely with other affiliated research sites to maintain these high standards.
NHO Revive, based in Lincoln, Nebraska, conducts clinical trials in various areas, including lymphoma, multiple myeloma, myelofibrosis, and breast, lung, and other solid tumor cancers. The organization's work is focused on moving potential new therapies forward and improving patient outcomes.
The summit will provide NHO Revive with a platform to share its expertise and learn from others. The team is eager to engage with sponsors, CROs, and fellow research sites to foster a collaborative environment that benefits all parties involved.
As NHO Revive prepares to attend the SCRS Global Site Solutions Summit 2026, the organization remains committed to its mission of improving patient care through innovative clinical research.